Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085826 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00085826 is a Phase 3 study of Non-Small Cell Lung Cancer that has completed, run by Astellas Pharma. The registered enrollment target is 600 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT00085826, a Phase 3 study of Non-Small Cell Lung Cancer, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study is to determine if Aptosyn, when given in combination with Taxotere, will result in prolonged survival when compared to Taxotere alone. This study will also help determine tumor response rates, and the safety profile of Aptosyn in combination with Taxotere. This study has been completed and a publication is pending.
Conditions Studied
Interventions
- DRUG Exisulind
Study Locations (20)
Colorado
- Rocky Mountain Cancer Center - Boulder
- Rocky Mountain Cancer Centers - Colorado Springs
- RMCC - Denver
- 12. Rocky Mountain Cancer Centers-Englewood - Englewood
- Rocky Mountain Cancer Centers - Englewood
- Rocky Mountain Cancer Centers - Fort Collins
- Rocky Mountain Cancer Centers - Littleton
- Rocky Mountain Cancer Centers - Thornton
California
- Pacific Coast Hematology/Oncology Medical Group, Inc. - Fountain Valley
- California Cancer Care, Inc. - Greenbrae
- Scripps Cancer Center - San Diego
- Sharp Clinical Oncology Research - San Diego
- Redwood Regional Medical Group - Santa Rosa
Arizona
- Northern Arizona Hematology and Oncology Associates - Flagstaff
- Hematology & Oncology Associates - Phoenix
- Northern Arizona Hematology & Oncology Associates - Sedona
- Arizona Clinical Research Center - Tucson
Alabama
- Birmingham Hematology Oncology Associates - Birmingham
- Birmingham Hematology and Oncology Associates, LLC - Birmingham
Arkansas
- Arkansas Oncology Associates, PA - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2001-04 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085826
The ClinicalTrials.gov registry entry for NCT00085826 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exisulind is the first listed.
NCT00085826 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00085826 about?
NCT00085826 is a clinical study titled "A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients". Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study is to determine if Aptosyn, when given in combination with Taxotere, will result in prolonged surviva...
What is the current status of trial NCT00085826?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2001-04. Estimated completion is 2004-12.
What conditions does trial NCT00085826 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00085826?
The interventions under investigation include: Exisulind (DRUG).
Who is sponsoring clinical trial NCT00085826?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085826 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.